Main content

    Stroke / TIA Clinical Trials

    Sutter Health participates in clinical trials related to Stroke and TIA throughout their Northern California facilities. See the listing below for an overview of current trials, including contact information. For some trials, more detailed information can be found via the title link to ClinicalTrials.gov.

    Title: Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) TrialOpens in a new window external site
    Description: To determine whether clopidogrel 75 mg/day by mouth after a loading dose of 600 mg is effective in preventing major ischemic vascular events at 90 days when subjects are randomized within 12 hours of last known free of symptoms in patients receiving asprin 50-300 mg/day.
    Investigator: Wendy Brown, MD
    Eligibility: Patients 18 years of age or older with an ABCD2 score > or equal to 4.
    Status: Active and open to enrollment
    Location: Sutter Medical Center, Sacramento/Sutter Roseville Medical Center
    Contact: Theresa Carter (SRMC) 916-781-4036 Email: CarterT3@sutterhealth.org
    Barbara Welcher (SMCS) 916-454-6907 Email: WelcheB@sutterhealth.org


    Title: Albumin in Acute Stroke (ALIAS) Trial-Part 2: A Phase III, Randomized, Multicenter Clinical Trial of High-Dose Albumin Therapy for Neuroprotection in Acute Ischemic Stroke (National Institute of Neurological Disorders and Stroke) (NINDS, 2U01NS40406-04Opens in a new window external site
    Description: The goal of the trial is to determine whether human albumin, administered within 5 hours of symptom onset, improves the 3-month outcome of subjects with acute ischemic stroke
    Investigator: Nobl Barazangi, MD PhD
    Eligibility: Acute ischemic stroke with NIHSS >6; able to enroll within 5 hours of stroke onset
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Jessica Redford, RN 415-600-1781
    Email: RedfordJ@cpmri.org


    Title: IV Thrombolysis in Anticoagulated Acute Stroke Patients
    Description: Retrospective study of outcomes and safety of patients who receive off-label IV rt-PA despite full anticoagulation
    Investigator: Nobl Barazangi, MD PhD
    Eligibility: Retrospective
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Jessica Redford, RN 415-600-1781
    Email: RedfordJ@cpmri.org


    Title: Platelet- Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial.Opens in a new window external site
    Description: A prospective randomized double-blind multicenter trial; the primary objective is to determine whether clopidogrel 75mg/day bu mouth after loading dose of 600mg of clopidogrel is effective in preventing major ischemic vascular events ischemic stroke, myocardial infarction, and ischemic vascular death) at 90 days when initiated within 12 hours of TIA or minor ischemic stroke onset in patients receiving aspirin 50-325 mg/day.
    Investigator: Nobl Barazangi, MD PhD
    Eligibility: TIA or minor stroke; must be enrolled within 12 hours of symptom onset.
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Jessica Redford, RN 415-600-1781
    Email: RedfordJ@cpmri.org


    Title: Expanding the Time Window for IV Thrombolysis with rt-PA in Acute Ischemic Stroke Patients Using Computed Tomography Perfusion Imaging: The PERFusion Use in Stroke Evaluation (PERFUSE) Study (Sutter Pacific Medical Foundation)Opens in a new window external site
    Description: A phase II trial, evaluating the utility of 64 slice CT perfusion (CTP) in acute ischemic stroke (AIS) patients. The main aim is to determine which aspects of CTP imaging can aid in expanding the time window for thrombolysis with IV (rt-PA) in AIS patients up to 6 hours after symptom onset.
    Investigator: Nobl Barazangi, MD PhD
    Eligibility: Active ischemic stroke within 6 hours of symptom onset received IV rt-PA and have CT perfusion imaging
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Jessica Redford, RN 415-600-1781
    Email: RedfordJ@cpmri.org


    Title: Advancing Telestroke Care: A Prospective Observational StudyOpens in a new window external site
    Description: This study will promote the development and economic sustainability of telemedicine for acute stroke treatment.
    Investigator: Nobl Barazangi, MD PhD
    Eligibility: Patients treated for acute or subactue ischemic stroke in participating hospitals.
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Jessica Redford, RN 415-600-1781
    Email: RedfordJ@cpmri.org


    Title: Stroke Hyperglycemia Insulin Network Effort (SHINE) TrialOpens in a new window external site
    Description: A multicenter, randomized, controlled clinical trial of 1400 patients. The study hypotheses are that treatment of hyperglycemic acute ischemic stroke patients with targeted glucose concentration (80mg/dL - 130 mg/dL) will be safe and result in improved 3 month outcome after stroke.
    Investigator: Nobl Barazangi, MD PhD
    Eligibility: Acute ischemic stroke within 12 hours of stroke onset, with a known history of diabetes or hyperglycemia on admission.
    Status: Active and soon open CPMC to enroll
    Location: California Pacific Medical Center
    Contact: Jessica Redford, RN 415-600-1781
    Email: RedfordJ@cpmri.org

    Title: CODMAN Enterprise Vascular Reconstruction Device and Delivery System
    Description: Placement of cerebral coils/stents after stroke
    Investigator: David Bonovich, MD
    Eligibility: Subjects undergoing brain coil/stent placement - Humanitarian use device only
    Status: Active and open to enrollment
    Location: Eden Medical Center
    Contact: Lorna Beccaria, RN, CCRC Study Coordinator 510-727-8267
    Email: BeccarL@sutterhealth.org


    Title: Neuroform micordelivery Stent System
    Description: Placement of cerebral coils/stents after stroke
    Investigator: David Bonovich, MD
    Eligibility: Subjects undergoing brain coil/stent placement - Humanitarian use device only
    Status: Active and open to enrollment
    Location: Eden Medical Center
    Contact: Lorna Beccaria, RN, CCRC Study Coordinator 510-727-8267
    Email: BeccarL@sutterhealth.org


    Title: Wingspan Stent System With Gateway PTA Balloon Catheter
    Description: Placement of cerebral coils/stents after stroke
    Investigator: David Bonovich, MD
    Eligibility: Subjects undergoing brain coil/stent placement - Humanitarian use device only
    Status: Active and open to enrollment
    Location: Eden Medical Center
    Contact: Lorna Beccaria, RN, CCRC Study Coordinator 510-727-8267
    Email: BeccarL@sutterhealth.org


    Title: Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial. Opens in a new window external site
    Description: To determine whether clopidogrel 75 mg/day by mouth after a loading dose of 600 mg is effective in preventing major ischemic vascular events at 90 days when subjects are randomized within 12 hours of TIA in patients receiving aspirin 50-325 mg/day.
    Investigator: Frank Kim, MD
    Eligibility: Subjects with Transient Ischemic Attack (TIA)
    Status: Active and open to enrollment
    Location: Eden Medical Center
    Contact: Lorna Beccaria, RN, CCRC 510-727-8267
    Email: BeccarL@sutterhealth.org


    Title: Antihypertensive Treatment of Acute Cerebral Hemorrhage-II (ATACH-II)Opens in a new window external site
    Description: Determine the therapeutic benefit of intensive SBP treatment compared with standard SBP treatment in reducing the proportion of patients with death and disability at day 90 among subjects with ICH treated within 3 hours of symptom onset.
    Investigator: Mohammad Mahmood, MD
    Eligibility: 18 years and older and less than 90 years. IV nicardipine can be initiatited within 3 hours of symptom onset.
    Status: Active and open to enrollment
    Location: Sutter Roseville Medical Center
    Contact: Theresa Carter 916-781-4036
    Email: CarterT3@sutterhealth.org


    Title: The S.M.A.R.T. Approach to Stroke Treatment
    Description: To evaluate, retrospectively, CPMC's Comprehensive Stroke Care Center's experience with the Simplified Management of Acute stroke using Revised Treatment criteria (SMART) approach towards treating stroke patients
    Investigator: David Tong, MD
    Eligibility: Retrospective study of all stroke patients treated at CPMC, especially those receiving acute stroke therapy
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Jessica Redford, RN 415-600-1781
    Email: RedfordJ@cpmri.org


    Title: Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients with Stable Ischemic Stroke (Protocol SB-STR01)
    Description: The primary objective of this project is to prescreen Sutter neurology patients who have been diagnosed with an ischemic stroke through chart review and visit with physican, to determine if they are eligible for the study titled: “A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients with Stable Ischemic Stroke
    Investigator: Gregory LeBleu, MD
    Eligibility: Patients 18-75 with a history of one (1) ischemic stroke, who are six (6) months to three (3) years out from Stoke and not improving in medical health.
    Status: Active and open to enrollment
    Location: Sutter Rehab/SNI/SIMR
    Contact: Debbie Jacobs, RN, 916-453-5745
    Email: jacobsda@sutterhealth.org


    Title: CLOTBUST ER A phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Combined Lysis of Thrombus with Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization (ClOTBUST-ER) in Acute Ishcemic Stroke
    Description: The primary objective of this study is to assess the efficacy of combined treatment with transcranial US using the SonoLysis Headframe and systemic tPA (Target group) compared to systemic tPA alone (Control group) in subjects with acute ischemic stroke. The primary efficacy endpoint is the proportion of subjects in the Treatment vs Control groups with mRS 0-1 scores at 90 days.
    Investigator: Asim Mahmood, MD
    Eligibility: Open.
    Status: Active and open to enrollment
    Location: Sutter Roseville Medical Center
    Contact: Tess Carter, DNP, FNP-BC, 916-801-5213
    Email: CarterT3@sutterhealth.org


    > See All Neurology Clinical Trials by Condition